

October 04, 2017

## **BioNTech Manufacturing Subsidiary, EUFETS, Becomes BioNTech Innovative Manufacturing Services**

**- Expansion and re-branding to ensure continued growth -**

**Mainz, Germany, October 04, 2017** – BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that its manufacturing subsidiary, EUFETS GmbH, has been re-branded as BioNTech Innovative Manufacturing Services. Furthermore, to prepare for further growth in response to increasing demand for cell and gene therapy products, in particular for CAR-T and T-Cell immunotherapies, BioNTech Innovative Manufacturing Services will significantly increase its production capacity by doubling cleanroom space and expanding development and quality control areas in a new facility.

BioNTech Innovative Manufacturing Services, based in Idar-Oberstein, Germany, is one of the oldest and most experienced GMP-certified contract development and manufacturing organizations in the world, specializing in cell and gene therapy products such as viral vectors, cellular products and *in vitro* transcribed mRNA. For more than 20 years, it has supplied important cell and gene therapy medicinal products worldwide. The subsidiary is also responsible for the manufacturing of BioNTech's proprietary, leading-edge mRNA immunotherapy programs including its individualized IVAC® cancer vaccines for clinical development, which is complemented by a second BioNTech mRNA manufacturing facility currently under construction at the Company's headquarters in Mainz, Germany.

"This strategic expansion of BioNTech Innovative Manufacturing Services will also enable production of commercial quantities of cell and gene therapy products for our customers, representing a major milestone in our manufacturing history," said Dr. Klaus Kühnlcke, Managing Director of BioNTech Innovative Manufacturing Services.

Sean Marett, COO of BioNTech, added, "We continue to invest heavily in manufacturing of individualized treatment concepts. CAR-T and TCR autologous therapies are expected to play an important role in the treatment of cancer, and state-of-the-art, single patient batch manufacturing of such therapies in sufficient capacity is critical to that role. Given BioNTech's focus on individualized immunotherapies for the treatment of cancer, we have taken the opportunity to re-brand EUFETS to be a more visible part of the BioNTech brand."

###

**For more information, please contact:**

**BioNTech AG**

Regina Jehle

Tel: +49 6131 9084 1273

Email: [Regina.Jehle@biontech.de](mailto:Regina.Jehle@biontech.de)

### **About BioNTech AG**

BioNTech is Europe's largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all building blocks for

individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech's approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech's financial shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.

More information about BioNTech is available at [www.biontech.de](http://www.biontech.de).